Abstract

This paper presents a new concept combining flexible organic light-emitting diode (OLED) display technology with fluorescent biorecognition microarray technology to fabricate point-of-care immunobiosensors. Our approach is designed to leverage commercial OLED display technology to reduce pre-functionalized biosensor substrate costs to pennies per ${cm}^{2}$ combined with leveraging the display industries ability to manufacture an immense number of low-cost consumer electronic products annually. For this work, we demonstrate that our new approach using high brightness flexible OLED display technology combined with a charge integrating readout circuit and optical filters can offer point-of-care diagnostic sensitivity at or below 10 pg/mL, which approaches the lower limit of detection (LLOD) of typical clinical laboratory instrumentation.

© 2015 IEEE

PDF Article

References

You do not have subscription access to this journal. Citation lists with outbound citation links are available to subscribers only. You may subscribe either as an OSA member, or as an authorized user of your institution.

Contact your librarian or system administrator
or
Login to access OSA Member Subscription

Cited By

You do not have subscription access to this journal. Cited by links are available to subscribers only. You may subscribe either as an OSA member, or as an authorized user of your institution.

Contact your librarian or system administrator
or
Login to access OSA Member Subscription